• What Rheumatologists Need to Know About Janus Kinase Inhibitors

    1 month ago - By Healio

    Janus kinase inhibitors have grown into a promising drug class for the treatment of rheumatoid arthritis, as these have an oral route of administration and are effective in patients with inadequate response to methotrexate, patients who have failed biologics and have helped patients who are methotrexate-naïve.In 2012, the first Janus kinase inhibitor, 5-mg twice-daily tofacitinib , was approved in the United States as monotherapy and in combination with methotrexate for patients with rheumatoid arthritis who responded poorly to methotrexate. In January 2017, the 2-mg and 4-mg twice-daily...
    Read more ...